- Conditions
- Healthy
- Interventions
- Denosumab
- Drug
- Lead sponsor
- Samsung Bioepis Co., Ltd.
- Industry
- Eligibility
- 28 Years to 55 Years · Male only
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- SB26, Placebo
- Drug
- Lead sponsor
- Samsung Bioepis Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Advanced Solid Tumors
- Interventions
- E303
- Drug
- Lead sponsor
- Samsung Bioepis Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Fairfax, Virginia
- Conditions
- Age-Related Macular Degeneration
- Interventions
- SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Samsung Bioepis Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 19
- States / cities
- Poway, California • Colorado Springs, Colorado • Fort Myers, Florida + 16 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- SB15 (Proposed aflibercept biosimilar), Eylea (Aflibercept)
- Drug
- Lead sponsor
- Samsung Bioepis Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Colorado Springs, Colorado • Chevy Chase, Maryland • Abilene, Texas